Lee A Albacker
Overview
Explore the profile of Lee A Albacker including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
59
Citations
3935
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Sharaf R, Frampton G, Albacker L
PLoS One
. 2022 Aug;
17(8):e0272707.
PMID: 36006930
Telomerase-mediated lengthening is a mechanism by which some cancer cells avoid senescence-mediated cell cycle arrest due to shortened telomeres. By reverse transcribing an RNA template, encoded by TERC, the enzyme...
12.
Ebot E, Duncan D, Tolba K, Fabrizio D, Frampton G, Comment L, et al.
NPJ Precis Oncol
. 2022 Jun;
6(1):44.
PMID: 35739333
NCCN guidelines for first-line treatment of advanced non-squamous non-small-cell lung cancer (NSCLC) patients without targetable driver alterations includes either immunotherapy alone or in combination with chemotherapy. In this study, we...
13.
Furman C, Puyang X, Zhang Z, Wu Z, Banka D, Aithal K, et al.
Mol Cancer Ther
. 2022 Jun;
21(6):890-902.
PMID: 35642432
Summary: H3B-6545 is an ERα covalent antagonist that exhibits encouraging preclinical activity against CDK4/6i naïve and resistant ERαWT and ERαMUT tumors.
14.
Papillon-Cavanagh S, Hopkins J, Ramkissoon S, Albacker L, Walsh A
Commun Med (Lond)
. 2022 May;
1:56.
PMID: 35602225
Background: Tumor mutational burden (TMB) has been proposed as a predictive biomarker of response to immunotherapy. Efforts to standardize TMB scores for use in the clinic and to identify the...
15.
Murugesan K, Jin D, Comment L, Fabrizio D, Hegde P, Elvin J, et al.
Oncologist
. 2022 May;
27(9):732-739.
PMID: 35598202
Background: We sought to characterize response to immune checkpoint inhibitor (ICI) in non-squamous non-small cell lung cancer (NSCLC) across various CD274 copy number gain and loss thresholds and identify an...
16.
Ishiyama N, OConnor M, Salomatov A, Romashko D, Thakur S, Mentes A, et al.
Cancer Res
. 2022 May;
83(9):1531-1542.
PMID: 35503682
Significance: This study identified new oncogenic HER2 allosteric mutations, including ECD mutations that share covalent dimerization as a mechanism of oncogenicity, suggesting the need for novel inhibitors to treat HER2-mutant...
17.
Sharaf R, Montesion M, Hopkins J, Song J, Frampton G, Albacker L
Genome Med
. 2022 Mar;
14(1):25.
PMID: 35227290
Background: Cancer cells can proliferate indefinitely through telomere maintenance mechanisms. These mechanisms include telomerase-dependent elongation, mediated by TERT activation, and alternative lengthening of telomeres (ALT), linked to loss of ATRX...
18.
Silverman I, Li M, Murugesan K, Krook M, Javle M, Kelley R, et al.
J Mol Diagn
. 2022 Feb;
24(4):351-364.
PMID: 35176488
Cholangiocarcinoma (CCA) is a heterogeneous biliary tract cancer with a poor prognosis. Approximately 30% to 50% of patients harbor actionable alterations, including FGFR2 rearrangements. Pemigatinib, a potent, selective fibroblast growth...
19.
Blum J, Laird A, Litton J, Rugo H, Ettl J, Hurvitz S, et al.
Clin Cancer Res
. 2022 Jan;
28(7):1383-1390.
PMID: 35091441
Purpose: PARP inhibitors (PARPi) have demonstrated efficacy in tumors with germline breast cancer susceptibility genes (gBRCA) 1 and 2 mutations, but further factors influencing response to PARPi are poorly understood....
20.
Schneider B, Jiang G, Ballinger T, Shen F, Chitambar C, Nanda R, et al.
J Clin Oncol
. 2021 Dec;
40(4):345-355.
PMID: 34910554
Purpose: Patients with triple-negative breast cancer (TNBC) with residual disease after neoadjuvant chemotherapy (NAC) have high risk of recurrence with prior data suggesting improved outcomes with capecitabine. Targeted agents have...